Skip to main content

Table 1 Passive immunotherapy with monoclonal antibodies

From: Potential sources of interference on Abeta immunoassays in biological samples

Drug name

Sponsor

Status

Aβ epitope

Reference

Passive immunotherapy with mAbs

   Bapineuzumab

J & J

III

1-5

[36, 37]

 

Elan

 

Conformational and linear

 
 

Pfizer

   

   Solanezumab

Lilly

III

13-28

[38, 39]

   

Linear

 

   Gantenerumab

Roche

II

Conformational

[40, 41]

   Ponezumab

Pfizer

II (stopped)

33-40

[42]

   

Linear

 

   Crenezumab

Genentech

II

1-15

[43]

   

Conformational

 

   BAN2401

Eisai

I

Amino-terminal

 
   

Conformational

 

Passive immunotherapy with intravenous IgGs

   Octagam

Octapharma

II

 

[44]

   Newgam

Sutter Health

II

  

Active immunotherapy, vaccines

   ACC-001

J & J

II

1-7

[45]

 

Wyeth

   

   CAD106

Novartis

II

1-6

[46]

   ACI-24

AC Immune

II

1-15

[43]

   Affitope AD02

GSK

Affiris

II

Mimick of amino terminus

[47]

  1. Aβ, β-amyloid; GSK, GlaxoSmithKline; J & J, Johnson and Johnson.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193